[go: up one dir, main page]

CL2018003324A1 - Antagonistas del receptor de angiotensina-1 - Google Patents

Antagonistas del receptor de angiotensina-1

Info

Publication number
CL2018003324A1
CL2018003324A1 CL2018003324A CL2018003324A CL2018003324A1 CL 2018003324 A1 CL2018003324 A1 CL 2018003324A1 CL 2018003324 A CL2018003324 A CL 2018003324A CL 2018003324 A CL2018003324 A CL 2018003324A CL 2018003324 A1 CL2018003324 A1 CL 2018003324A1
Authority
CL
Chile
Prior art keywords
angiotensin
receptor antagonists
pregnancy
formula
compounds
Prior art date
Application number
CL2018003324A
Other languages
English (en)
Inventor
Jacek Stalewski
Edward Earl Cable
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of CL2018003324A1 publication Critical patent/CL2018003324A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En un aspecto, esta descripción presenta compuestos de la fórmula (I) o una sal farmacéuticamente aceptable de los mismos: AA1-Arg-Val-AA4-AA5-His-Pro-AA8-OH (I), en la que AA1, AA4, AA5 y AA8 se definen en la especificación. Los compuestos de la fórmula (I) se pueden utilizar para tratar la hipertensión (por ejemplo, hipertensión inducida por el embarazo), preclamsia o una enfermedad renal inducida por el embarazo.
CL2018003324A 2016-06-02 2018-11-22 Antagonistas del receptor de angiotensina-1 CL2018003324A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662344831P 2016-06-02 2016-06-02
EP16185403 2016-08-23

Publications (1)

Publication Number Publication Date
CL2018003324A1 true CL2018003324A1 (es) 2019-06-07

Family

ID=58992873

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003324A CL2018003324A1 (es) 2016-06-02 2018-11-22 Antagonistas del receptor de angiotensina-1

Country Status (16)

Country Link
EP (1) EP3464324B1 (es)
JP (1) JP7139251B2 (es)
BR (1) BR112018074190A2 (es)
CL (1) CL2018003324A1 (es)
DK (1) DK3464324T3 (es)
ES (1) ES2878153T3 (es)
HU (1) HUE054334T2 (es)
IL (1) IL262981B2 (es)
JO (1) JOP20170133B1 (es)
MX (1) MX2018014364A (es)
MY (1) MY191062A (es)
PH (1) PH12018502440A1 (es)
PL (1) PL3464324T3 (es)
SI (1) SI3464324T1 (es)
UA (1) UA123367C2 (es)
ZA (1) ZA201807767B (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE026131T2 (en) * 2008-12-29 2016-05-30 Trevena Inc Beta-arresin effector and preparations and methods for their use

Also Published As

Publication number Publication date
IL262981A (en) 2018-12-31
UA123367C2 (uk) 2021-03-24
DK3464324T3 (da) 2021-06-28
EP3464324B1 (en) 2021-04-07
SI3464324T1 (sl) 2021-08-31
ZA201807767B (en) 2023-04-26
BR112018074190A2 (pt) 2019-03-26
IL262981B1 (en) 2023-09-01
HUE054334T2 (hu) 2021-08-30
JP2019520331A (ja) 2019-07-18
JOP20170133B1 (ar) 2022-03-14
PL3464324T3 (pl) 2021-10-25
MY191062A (en) 2022-05-30
EP3464324A1 (en) 2019-04-10
ES2878153T3 (es) 2021-11-18
IL262981B2 (en) 2024-01-01
PH12018502440A1 (en) 2019-09-09
JP7139251B2 (ja) 2022-09-20
MX2018014364A (es) 2019-02-14

Similar Documents

Publication Publication Date Title
BR112017024555A2 (pt) moduladores de ccr2
CY1123100T1 (el) Μεθοδος για την παρασκευη amg 416
UY36452A (es) Novedosos compuestos moduladores de fxr (nr1h4)
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
CL2017002401A1 (es) Anticuerpos contra icos
MX2017007941A (es) Anticuerpos antagonistas anti-axl.
MX2019003945A (es) Formas cristalinas y salinas de compuestos agonistas de ppar.
CU24481B1 (es) Moléculas de anticuerpo que se unen a lag-3
EA201791998A1 (ru) Альдегиды для лечения легочного фиброза, гипоксии и заболевания соединительной ткани и аутоиммунного заболевания
BR112016008541A2 (pt) composições úteis para tratar distúrbios relacionados a kit
MX2018013072A (es) Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
ES2897914T8 (es) Compuestos que contienen nitrógeno, adecuados para el uso en la producción de poliuretanos
MX2022015258A (es) Anticuerpos anti-cxcr5 y composiciones y usos de los mismos.
MX2016006199A (es) Inhibidores de replicacion del virus de influenza.
MX2016016534A (es) Compuestos ppar para uso en el tratamiento de enfermedades fibroticas.
HUE071358T2 (hu) Benzolszulfonamid vegyületek és terápiás szerként való alkalmazásuk
CY1125297T1 (el) Αναστολεις της il-8 για χρηση στην αγωγη της περιφερικης νευροπαθειας που επαγεται απο χημειοθεραπεια
CL2018003045A1 (es) Semaglutida en afecciones cardiovasculares.
MX2018002338A (es) Sondas para formar imagenes de proteina de huntingtina.
IL280191A (en) Solubilized apyrases, methods and use
EP3856174A4 (en) HDAC1, 2 INHIBITORS
MX372759B (es) Composiciones para usarse en mejorar la función renal.
BR112019011461A2 (pt) terapia celular à base de nk melhorada
AR100289A1 (es) Formas de un inhibidor de pi3k
CO2017007940A2 (es) Péptidos antagonistas prgc